
WAT tops Q2 estimates, raises its 2026 outlook and posts broad-based growth across organic and acquired businesses.
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
| Revenue (TTM) | $4.64B |
| Gross Profit (TTM) | $2.62B |
| EBITDA | $1.45B |
| Operating Margin | 9.42% |
| Return on Equity | 1.92% |
| Return on Assets | 3.56% |
| Revenue/Share (TTM) | $62.10 |
| Book Value | $155.78 |
| Price-to-Book | 2.67 |
| Price-to-Sales (TTM) | 8.62 |
| EV/Revenue | 9.77 |
| EV/EBITDA | 46.90 |
| Quarterly Earnings Growth (YoY) | -3.10% |
| Quarterly Revenue Growth (YoY) | 113.40% |
| Shares Outstanding | $98.19M |
| Float | $98.06M |
| % Insiders | 0.10% |
| % Institutions | 102.19% |
Volatility is currently contracting

WAT tops Q2 estimates, raises its 2026 outlook and posts broad-based growth across organic and acquired businesses.

Waters Corporation (WAT) Q2 2026 Earnings Call Transcript

Waters (WAT) came out with quarterly earnings of $3.05 per share, beating the Zacks Consensus Estimate of $3.01 per share. This compares to earnings of $2.95 per share a year ago.

Second Quarter 2026 Highlights Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses. Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.

The top five contributors for the quarter were MKS, Amphenol, Arista Networks, Bio-Techne, and Waters. The bottom five detractors for the quarter were Ross Stores, Arch Capital, Copart, Gartner, and Brown & Brown. We purchased shares in Verisk Analytics, the dominant provider of data and analytics to property and casualty insurers in the U.S.

Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Waters (WAT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Brings Xevo™ TQ Absolute XR Mass Spectrometer's industry-leading tandem quadrupole MS sensitivity to clinical applications across women's health, cancer assessment, and toxicology. Offers 5x greater sensitivity vs.

Waters Corporation remains a Hold as valuation concerns are balanced by ongoing synergy capture from its Becton, Dickinson acquisition. WAT's Q1 pro forma sales rose to $1.54B, with legacy revenue up 13% and recurring revenue surging 123%, signaling broad-based growth. Synergy realization is on track, with $55M+ cost savings and $50M revenue synergies targeted for 2026, supporting incremental EBITDA gains.

MILFORD, Mass., July 2, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) will hold its Q2 2026 financial results conference call on Tuesday, August 4, 2026, at 8:00 a.m.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on WAT and any ticker you trade — then tracks every position and per-strategy win rate.